<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083925</url>
  </required_header>
  <id_info>
    <org_study_id>TIPS-CX</org_study_id>
    <nct_id>NCT03083925</nct_id>
  </id_info>
  <brief_title>Viatorr CX Case-control Study for Complications of Portal Hypertension</brief_title>
  <acronym>VIATORR-CX</acronym>
  <official_title>Viatorr Control Expansion Compared to Bare-metal and Regular Viatorr for Complications of Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical benefits in the patients receiving Viatorr CX over a period of 12
      months of structured Follow-up (before TIPS, at TIPS, 1 week after TIPS, at 6 weeks, 4
      months, 6 months, 9 months, 12 months), regarding clinical endpoints, such as HE,
      readmission, liver injury, cardiac function, response to TIPS and the passive expansion of
      the stents in real life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Case-control study using the patients in the University Clinic Bonn receiving Viatorr CX
      (n=40), using a comparison ration 1:1:1 to Viatorr and bare metal stents.

      Of these patients, 20 patients will receive Viatorr CX and the assessement of the width of
      the stent as outlined in the JVIR-paper published this year.

      The Viatorr and BMS controls with similar age, gender, Child, MELD and indication for TIPS.

      A total of 125 patients with the primary composite-endpoint HE/readmission will be
      investigated Secondary endpoints are liver injury, cardiac function, response to TIPS and the
      passive expansion of the stents in real life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Readmissions</measure>
    <time_frame>12 months</time_frame>
    <description>Number of readmissions will be documented using a structured CRF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic encephalopathy (HE)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of Episodes of overt HE (West Haven Criteria &gt; Grad I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver injury</measure>
    <time_frame>12 months</time_frame>
    <description>Increase in liver function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to TIPS</measure>
    <time_frame>12 months</time_frame>
    <description>grade of ascites after TIPS</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Liver Cirrhoses</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Bare metal stent (BMS) TIPS</arm_group_label>
    <description>retrospective patients receiving BMS-TIPS for treatment of complications of portal hypertension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular Viatorr (RV) TIPS</arm_group_label>
    <description>retrospective patients receiving RV-TIPS for treatment of complications of portal hypertension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viatorr Control Expansion (VCX)TIPS</arm_group_label>
    <description>prospective patients receiving VCX-TIPS for treatment of complications of portal hypertension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TIPS</intervention_name>
    <description>Transjugular Intrahepatic Portosystemic Shunt</description>
    <arm_group_label>Bare metal stent (BMS) TIPS</arm_group_label>
    <arm_group_label>Regular Viatorr (RV) TIPS</arm_group_label>
    <arm_group_label>Viatorr Control Expansion (VCX)TIPS</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, stool, DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Case-control study using the patients in our center receiving Viatorr CX (n=40), using a
        comparison ration 1:1:1 to Viatorr and bare metal stents (all available data from our
        center). Thereby, we will choose 20 patients receiving Viatorr CX and the assessement of
        the width of the stent as outlined in the JVIR-paper published this year. The Viatorr and
        BMS controls with similar age, gender, Child, MELD and indication for TIPS. We will
        investigate a total 125 patients with the primary composite-endpoint HE/readmission, and
        secondary endpoints will be liver injury, cardiac function, response to TIPS and the
        passive expansion of the stents in real life.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suitable for TIPS

        Exclusion Criteria:

          -  Contraindication for TIPS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonel Trebicka, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratory for Liver Fibrosis and Portal Hypertension</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonel Trebicka, MD, PhD</last_name>
    <email>jonel.trebicka@ukbonn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Praktiknjo, MD</last_name>
    <email>Michael.Praktiknjo@ukbonn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laboratory for Liver Fibrosis and Portal Hypertension</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonel Trebicka, MD, PhD</last_name>
      <email>jonel.trebicka@ukbonn.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2017</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Jonel Trebicka</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

